SCHEMBL6570169

SCHEMBL6570169

O=C(N/N=C\c1cc(O)ccc1O)c1cccc(Cl)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.77
MEN1 O00255 7/20 0.62
KMT2A Q03164 7/20 0.62
NPC1 O15118 7/20 0.62
TDP1 Q9NUW8 1/20 0.62
RAB9A P51151 7/20 0.62
KLF5 Q13887 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.60
KDM4E B2RXH2 3/20 0.60
LMNA P02545 3/20 0.60
POLB P06746 2/20 0.60
HTT P42858 2/20 0.60
PSMD14 O00487 1/20 0.60
MMP2 P08253 1/20 0.60
BLM P54132 1/20 0.60
MITF O75030 1/20 0.60
GPR174 Q9BXC1 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MAPT P10636 4/20 0.56
NFKB1 P19838 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6570173 1.00 KDM1A (0.77) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL684639 0.92 KDM1A (0.81) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL6751419 0.92 KDM1A (0.81) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL6751416 0.92 KDM1A (0.81) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL6569227 0.90 KDM1A (0.77) KDM1AMEN1KMT2ANPC1RAB9A
SCHEMBL6569224 0.90 KDM1A (0.77) KDM1AMEN1KMT2ANPC1RAB9A
SCHEMBL684661 0.88 KDM1A (0.73) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL684841 0.88 KDM1A (0.73) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL684939 0.87 KDM1A (1.00) KDM1AMEN1KMT2ANPC1TDP1
SCHEMBL6751409 0.85 KDM1A (0.85) KDM1AMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM1A 2684/4885MEN1 2514/4885KMT2A 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.